Angiotensin-Converting Enzyme Inhibitors vs. Angiotensin Receptor Blockers for the Treatment of Hypertension in Adults With Type 2 Diabetes: Why We Favour Angiotensin Receptor Blockers

Publication date: April 2018Source: Canadian Journal of Diabetes, Volume 42, Issue 2Author(s): Thomas A. Mavrakanas, Mark L. LipmanAbstractCardiovascular disease is the principal cause of morbidity and mortality in patients with diabetes mellitus. The incidence or progression of kidney disease is also common in these patients. Several clinical trials have established the efficacy of angiotensin receptor blockers for the prevention of adverse cardiovascular and renal outcomes in this population and are summarized in this review article. Head-to-head comparison of angiotensin receptor blockers with angiotensin-converting enzyme inhibitors has shown similar cardioprotective and renoprotective properties of both medication classes. However, angiotensin receptor blockers have an improved safety profile with fewer episodes of cough and angioedema and may be the agent of choice in patients with diabetes and hypertension. Novel therapeutic strategies, such as those that include a mineralocorticoid receptor blocker or a selective sodium-glucose cotransporter type 2 inhibitor, may further protect patients with diabetes from cardiovascular and renal complications.RésuméLes maladies cardiovasculaires sont la principale cause de morbidité et de mortalité chez les patients atteints de diabète sucré. L'incidence ou la progression de la maladie rénale est également fréquente chez ces patients. Dans le présent article de revue, nous résumons de nombreux essais cliniques qui ont per...
Source: Canadian Journal of Diabetes - Category: Endocrinology Source Type: research